

Estimating the Impact of USAID-Funded Contraceptives: Tajikistan



Overall Contraceptive Use by Method

Estimated Contraceptive Users, 2020-2024

	2020	2021	2022	2023	2024
Condoms	63,000	65,000	66,000	68,000	69,000
Pills	34,000	35,000	35,000	36,000	37,000
Injectables	18,000	18,000	19,000	19,000	20,000
Implants	2,000	2,000	2,000	2,000	2,000
IUD	304,000	313,000	321,000	329,000	336,000
Sterilization	38,000	39,000	40,000	41,000	42,000
Other	18,000	18,000	19,000	19,000	20,000
Total	477,000	490,000	502,000	514,000	526,000

Source: Method Mix from 2023 DHS applied to modern user estimates from FP2030 2025 Report

USAID's Contribution to Contraceptive Procurement

USAID-Funded Contraceptive Commodities Procured, 2020-2024

	2020	2021	2022	2023	2024
Condoms	0	0	36,750	0	33,750
Pills	0	0	0	0	0
Injectables	0	0	0	0	0
Implants	0	0	0	0	0
IUD	0	0	0	0	0
Other	0	0	0	0	0

Source: RH Viz, April 2025

Note: "Other" includes emergency contraception, syringes and accessories, standard days method, and trocars. Condom values have been adjusted to exclude condoms procured for HIV programs. For USAID, an assumption was made that 75% of condoms were procured for HIV programs (based on reporting from GHSC-PSM)

Estimating the Comparative Value of USAID's Contraceptive Procurement

Total USD Value of Donor-Funded Contraceptive Products Procured, by Funder, 2020-2024

	2020	2021	2022	2023	2024
UNFPA Supplies	\$109,328	\$457,533	\$0	\$145,321	\$135,507
USAID	\$0	\$0	\$1,198	\$0	\$1,100
Other Donor	\$0	\$0	\$0	\$0	\$0
NGO/SMO	\$0	\$0	\$0	\$0	\$0
Other	\$0	\$0	\$68,900	\$65,250	\$0
UNFPA Co Financing	\$110,436	\$0	\$0	\$0	\$0
Total	\$219,764	\$457,533	\$70,098	\$210,571	\$136,607
% USAID	0%	0%	2%	0%	1%

Source: RH Viz, April 2025

Note: Values are only for the commodities and do not include estimates of the shipping and associated costs to get those products to the country. Values exclude personal lubricants. Condom values have been adjusted to exclude condoms procured for HIV programs. For USAID, an assumption was made that 75% of condoms were procured for HIV programs (based on reporting from GHSC-PSM) and for Global Fund, an assumption was made that 100% of condoms were procured for HIV.

Estimating the Impacts of Donor-Funded Contraceptives and USAID's Contribution

Estimated Impacts of Contraceptive Products Procured in 2024

	Impacts of Total Commodities (all funders)	Impacts of USAID-funded Commodities only	Impacts of Total Commodities <u>without</u> USAID-funded Commodities	% of Total Impact that came from USAID
Demographic impacts				
<i>Unintended pregnancies averted</i>	13,900	0	13,900	0%
<i>Live births averted</i>	2,600	0	2,600	0%
<i>Abortions averted</i>	9,900	0	9,900	0%
Health impacts				
<i>Maternal deaths averted</i>	0	0	0	#DIV/0!
<i>Child deaths averted*</i>	40	0	40	0%
<i>Unsafe abortions averted</i>	5,760	30	5,730	1%
Couple Years of Protection (CYPs)				
Total CYPs (FP only)	32,877	281	32,596	1%

Notes: Impact estimates are Service-Lifespan impacts based on default Impact2 Model values; RH Viz does not specify implant or injectable type, so implant procurement was split evenly into 5-year and 3-year implants, and injectables were assumed to be 3-month injectables; 2025 commitments (in terms of \$ or products) not available, so 2024 is a proxy to estimate the impact of USAID funded FP commodity procurement

* Estimates of child deaths averted may be unreliable because there is currently very limited data about the linkages between CPR, birth spacing and child mortality. This part of Impact 2 will be updated as improved research becomes available.